Covered recipient · General Payments record
JAVIER ALONSO-LLAMAZARES
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$146,903.79
337 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $78,600.00 | 33 |
| Consulting Fee | $27,380.00 | 8 |
| Travel and Lodging | $13,912.77 | 89 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $13,080.00 | 5 |
| Food and Beverage | $8,895.02 | 198 |
| Honoraria | $5,000.00 | 2 |
| Education | $36.00 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 2 of 7; records 51–100 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAVIER ALONSO-LLAMAZARES
NPI 1356315485 · CMS profile ID 151705
Allopathic & Osteopathic Physicians / Dermatology
CORAL GABLES, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 7; records 51–100 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1356315485?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAVIER ALONSO-LLAMAZARES, NPI 1356315485, CMS profile ID 151705. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356315485?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). JAVIER ALONSO-LLAMAZARES, NPI 1356315485, CMS profile ID 151705. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356315485?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- JAVIER ALONSO-LLAMAZARES, NPI 1356315485, CMS profile ID 151705, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 337 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1356315485?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
337 matching records · $146,903.79 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 337.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $480.06 | 10/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657887139 | CMS |
| Lilly USA, LLC | $80.00 | 10/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657887165 | CMS |
| Lilly USA, LLC | $19.26 | 10/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657890761 | CMS |
| Lilly USA, LLC | $14.40 | 10/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657890763 | CMS |
| Regeneron Healthcare Solutions, Inc. | $28.46 | 10/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673327169 | CMS |
| Lilly USA, LLC | $2.17 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657870103 | CMS |
| Lilly USA, LLC | $9.99 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657870105 | CMS |
| Lilly USA, LLC | $1.28 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657873537 | CMS |
| Lilly USA, LLC | $288.02 | 10/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657877007 | CMS |
| Lilly USA, LLC | $4.25 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657877047 | CMS |
| Lilly USA, LLC | $17.00 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657880437 | CMS |
| Lilly USA, LLC | $4.25 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657880439 | CMS |
| Lilly USA, LLC | $7.23 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657880441 | CMS |
| Lilly USA, LLC | $1.28 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657880443 | CMS |
| Lilly USA, LLC | $17.00 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657880445 | CMS |
| Lilly USA, LLC | $6.38 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657883895 | CMS |
| Lilly USA, LLC | $28.90 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657883897 | CMS |
| Lilly USA, LLC | $3.00 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657883899 | CMS |
| Lilly USA, LLC | $39.95 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657883901 | CMS |
| Lilly USA, LLC | $1.91 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657887167 | CMS |
| Lilly USA, LLC | $25.50 | 10/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657887169 | CMS |
| Genentech USA, Inc. | $16.55 | 10/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681397999 | CMS |
| Novartis Pharmaceuticals Corporation | $115.59 | 10/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658972987 | CMS |
| Eli Lilly Export S.A. Puerto Rico Branch | $2,800.00 | 10/23/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657870063 | CMS |
| Eli Lilly Export S.A. Puerto Rico Branch | $2,450.00 | 10/23/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657877013 | CMS |
| Eli Lilly Export S.A. Puerto Rico Branch | $2,800.00 | 10/23/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657880407 | CMS |
| Merz North America, Inc. | $139.68 | 10/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 689352867 | CMS |
| UCB, Inc. | $18.13 | 10/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688241593 | CMS |
| UCB, Inc. | $20.66 | 10/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688241595 | CMS |
| UCB, Inc. | $2,500.00 | 10/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688241597 | CMS |
| Lilly USA, LLC | $97.48 | 10/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657887137 | CMS |
| Eli Lilly Export S.A. Puerto Rico Branch | $16.59 | 10/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657877015 | CMS |
| Lilly USA, LLC | $89.68 | 10/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657873535 | CMS |
| Lilly USA, LLC | $254.00 | 10/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657877011 | CMS |
| Lilly USA, LLC | $284.40 | 10/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657880403 | CMS |
| Lilly USA, LLC | $10.76 | 10/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657887163 | CMS |
| Lilly USA, LLC | $254.00 | 10/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657894073 | CMS |
| Lilly USA, LLC | $97.48 | 10/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657870061 | CMS |
| Lilly USA, LLC | $395.35 | 10/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657877009 | CMS |
| Encore Dermatology Inc. | $21.48 | 10/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698862979 | CMS |
| Celgene Corporation | $2.31 | 10/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672943979 | CMS |
| Mayne Pharma Inc. | $32.53 | 10/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705486431 | CMS |
| UCB, Inc. | $125.00 | 10/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688240381 | CMS |
| UCB, Inc. | $10.44 | 10/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688240189 | CMS |
| UCB, Inc. | $2,500.00 | 10/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688240191 | CMS |
| UCB, Inc. | $4.00 | 10/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688240193 | CMS |
| Novartis Pharmaceuticals Corporation | $22.75 | 10/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658972980 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $15.00 | 10/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684565759 | CMS |
| Encore Dermatology Inc. | $8.49 | 10/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698862975 | CMS |
| Merck Sharp & Dohme Corporation | $14.25 | 09/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695798811 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,474,839.08 | 162 |
| PY2024 | Recipient | $2,676.00 | 1 |
| PY2024 | Principal investigator | $1,733,600.42 | 298 |
| PY2023 | Recipient | $11,536.01 | 2 |
| PY2023 | Principal investigator | $477,143.57 | 62 |
| PY2022 | Principal investigator | $199,921.00 | 14 |
| PY2021 | Principal investigator | $952.00 | 1 |
| PY2020 | Recipient | $3,381.00 | 2 |
| PY2020 | Principal investigator | $3,482.66 | 5 |
| PY2019 | Recipient | $76.41 | 1 |
| PY2019 | Principal investigator | $854,916.93 | 60 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
162 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $13,365.00 | 12/25/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418528 |
| Principal investigator 1 | Incyte Corporation | $2,257.20 | 12/19/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530915 |
| Principal investigator 1 | Incyte Corporation | $3,594.60 | 12/19/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530928 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,151.00 | 12/19/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418443 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,338.40 | 12/18/2025 | Non-covered Recipient Entity Driven Research LLC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431600 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,425.00 | 12/16/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223289724 |
| Principal investigator 1 | Incyte Corporation | $1,011.60 | 12/11/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530944 |
| Principal investigator 1 | ABBVIE INC. | $1,939.50 | 12/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202528386 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 12/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240530906 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 12/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240530910 |
| Principal investigator 1 | Incyte Corporation | $818.10 | 12/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530919 |
| Principal investigator 1 | Incyte Corporation | $5,282.60 | 12/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530924 |
| Principal investigator 1 | Incyte Corporation | $9,527.80 | 12/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530932 |
| Principal investigator 1 | Incyte Corporation | $6,000.00 | 12/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530936 |
| Principal investigator 1 | Incyte Corporation | $5,213.20 | 12/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530940 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,790.00 | 12/01/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418520 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $18,476.90 | 12/01/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289059 |
| Principal investigator 1 | ABBVIE INC. | $19,397.40 | 11/25/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202525216 |
| Principal investigator 1 | Incyte Corporation | $3,150.00 | 11/25/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530885 |
| Principal investigator 1 | Incyte Corporation | $240.00 | 11/25/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530889 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 11/24/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418439 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,056.00 | 11/24/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418449 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,585.00 | 11/24/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418454 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 11/20/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202525042 |
| Principal investigator 1 | Incyte Corporation | $1,290.60 | 11/20/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530898 |
| Principal investigator 1 | Incyte Corporation | $4,723.20 | 11/14/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530902 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,527.00 | 11/13/2025 | Non-covered Recipient Entity Driven Research LLC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431598 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,700.00 | 11/12/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223288213 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,549.74 | 11/12/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223288281 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $99,284.12 | 11/10/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190311115 |
| Principal investigator 1 | Incyte Corporation | $1,285.20 | 11/07/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530894 |
| Principal investigator 1 | ABBVIE INC. | $1,784.70 | 11/05/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202523097 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,475.00 | 11/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223287933 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,577.00 | 11/03/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418465 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $10,061.29 | 10/30/2025 | Non-covered Recipient Entity Driven Research Llc | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235997659 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $97.50 | 10/28/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223287677 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,325.00 | 10/24/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418537 |
| Principal investigator 1 | Incyte Corporation | $1,290.60 | 10/23/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530872 |
| Principal investigator 1 | Incyte Corporation | $273.60 | 10/23/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530880 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,833.35 | 10/23/2025 | Non-covered Recipient Entity Driven Research LLC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431594 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,857.80 | 10/23/2025 | Non-covered Recipient Entity Driven Research LLC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431596 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,400.00 | 10/22/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287287 |
| Principal investigator 1 | ABBVIE INC. | $3,127.50 | 10/09/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202515863 |
| Principal investigator 1 | Incyte Corporation | $3,122.10 | 10/09/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530876 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,431.10 | 10/09/2025 | Non-covered Recipient Entity Driven Research LLC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431592 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $17,148.30 | 10/01/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286075 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,154.00 | 09/29/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418515 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,805.00 | 09/29/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418549 |
| Principal investigator 1 | Incyte Corporation | $1,558.80 | 09/23/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530863 |
| Principal investigator 1 | Incyte Corporation | $1,448.10 | 09/23/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530867 |
| Principal investigator 1 | Incyte Corporation | $2,422.80 | 09/18/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530848 |
| Principal investigator 1 | Incyte Corporation | $3,483.00 | 09/18/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530851 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,064.40 | 09/18/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223285702 |
| Principal investigator 1 | Incyte Corporation | $2,108.70 | 09/12/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530855 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,615.00 | 09/08/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418458 |
| Principal investigator 1 | ABBVIE INC. | $4,575.70 | 09/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202509610 |
| Principal investigator 1 | Incyte Corporation | $2,738.70 | 09/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530858 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,851.60 | 09/03/2025 | Non-covered Recipient Entity Driven Research Llc | A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1226081317 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,599.60 | 09/03/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285067 |
| Principal investigator 1 | Incyte Corporation | $927.90 | 08/26/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530843 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,774.00 | 08/25/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418484 |
| Principal investigator 1 | Incyte Corporation | $4,763.70 | 08/21/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530829 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,556.65 | 08/19/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223284369 |
| Principal investigator 1 | Incyte Corporation | $1,741.50 | 08/14/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530833 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,510.75 | 08/13/2025 | Non-covered Recipient Entity Driven Research LLC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431590 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,595.25 | 08/12/2025 | Non-covered Recipient Entity Driven Research LLC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431586 |
| Principal investigator 1 | Incyte Corporation | $3,106.80 | 08/07/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530835 |
| Principal investigator 1 | Incyte Corporation | $1,097.10 | 08/07/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530840 |
| Principal investigator 1 | ABBVIE INC. | $3,282.30 | 08/06/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202502326 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,774.00 | 08/01/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418496 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $21,594.30 | 08/01/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283725 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,028.90 | 08/01/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283727 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,300.00 | 07/28/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175188994 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47,360.00 | 07/28/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418490 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,500.00 | 07/25/2025 | Non-covered Recipient Entity Driven Research LLC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431588 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,500.00 | 07/18/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223282856 |
| Principal investigator 1 | Incyte Corporation | $380.70 | 07/17/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530825 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $18,891.60 | 07/17/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223282788 |
| Principal investigator 1 | Incyte Corporation | $3,109.50 | 07/10/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530814 |
| Principal investigator 1 | Incyte Corporation | $1,878.30 | 07/10/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530818 |
| Principal investigator 1 | ABBVIE INC. | $3,929.60 | 07/08/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497028 |
| Principal investigator 1 | Incyte Corporation | $2,422.80 | 07/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530822 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,272.40 | 07/02/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223282166 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,489.00 | 06/27/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418477 |
| Principal investigator 1 | Incyte Corporation | $380.70 | 06/24/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530791 |
| Principal investigator 1 | Janssen Research & Development, LLC | $30,320.00 | 06/23/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418434 |
| Principal investigator 1 | Incyte Corporation | $2,514.60 | 06/19/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530787 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $19,152.90 | 06/13/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223281260 |
| Principal investigator 1 | Incyte Corporation | $4,397.40 | 06/12/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530801 |
| Principal investigator 1 | Incyte Corporation | $77.40 | 06/12/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530809 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,272.40 | 06/06/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223280884 |
| Principal investigator 1 | Incyte Corporation | $2,669.40 | 06/05/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530795 |
| Principal investigator 1 | Incyte Corporation | $1,448.10 | 06/05/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530805 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 06/04/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175188921 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 06/04/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175188941 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 06/04/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175188965 |
| Principal investigator 1 | Janssen Research & Development, LLC | $291.00 | 06/04/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 06/04/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189251 |
| Principal investigator 1 | ABBVIE INC. | $5,272.40 | 06/03/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202488261 |
| Principal investigator 1 | Incyte Corporation | $5,049.90 | 05/28/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530779 |
| Principal investigator 1 | Eli Lilly and Company | $23,705.00 | 05/21/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187882376 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,060.00 | 05/21/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223280100 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,272.00 | 05/20/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223279968 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,000.00 | 05/19/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418471 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,101.00 | 05/15/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175188930 |
| Principal investigator 1 | Incyte Corporation | $2,975.40 | 05/08/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530783 |
| Principal investigator 1 | ABBVIE INC. | $4,106.40 | 05/07/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202482501 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,561.25 | 05/01/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223278788 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,404.60 | 05/01/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278796 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 04/28/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530762 |
| Principal investigator 1 | Incyte Corporation | $20,737.80 | 04/28/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530766 |
| Principal investigator 1 | Incyte Corporation | $6,000.00 | 04/28/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | No dispute reported | 06/30/2026 | 1240530770 |
| Principal investigator 1 | Incyte Corporation | $1,939.50 | 04/28/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530775 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,101.00 | 04/28/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175189060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,400.00 | 04/28/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189069 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,400.00 | 04/28/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,832.00 | 04/25/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418501 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,520.00 | 04/24/2025 | Non-covered Recipient Entity Driven Research LLC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431584 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,100.00 | 04/21/2025 | Non-covered Recipient Entity Driven Research Llc | A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1226081258 |
| Principal investigator 1 | Incyte Corporation | $820.80 | 04/15/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530758 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $950.26 | 04/11/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277974 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $31,320.90 | 04/11/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278014 |
| Principal investigator 1 | Incyte Corporation | $3,914.80 | 04/08/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530754 |
| Principal investigator 1 | Eli Lilly and Company | $4,035.00 | 04/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | No dispute reported | 06/30/2026 | 1187881374 |
| Principal investigator 1 | ABBVIE INC. | $2,763.60 | 04/03/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202472868 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,787.45 | 03/25/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223277017 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,400.00 | 03/24/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189053 |
| Principal investigator 1 | Incyte Corporation | $2,460.00 | 03/14/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530746 |
| Principal investigator 1 | Incyte Corporation | $1,664.10 | 03/11/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530741 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,506.00 | 03/11/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223276187 |
| Principal investigator 1 | ABBVIE INC. | $5,272.40 | 03/07/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202460678 |
| Principal investigator 1 | Incyte Corporation | $7,521.30 | 03/04/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530750 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,383.00 | 03/03/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175189110 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,646.00 | 03/03/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418507 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,556.00 | 02/27/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175188989 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,556.00 | 02/27/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189180 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,841.40 | 02/26/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275619 |
| Principal investigator 1 | Incyte Corporation | $9,047.80 | 02/25/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530958 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,288.00 | 02/24/2025 | Non-covered Recipient Entity Driven Research Llc | A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1226081249 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,451.60 | 02/24/2025 | Non-covered Recipient Entity Driven Research Llc | A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1226081253 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,425.00 | 02/21/2025 | Non-covered Recipient Entity Driven Research Llc | A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1235997657 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,844.75 | 02/20/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275425 |
| Principal investigator 1 | ABBVIE INC. | $2,940.40 | 02/06/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202447943 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,296.00 | 02/06/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175418542 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $29,486.60 | 02/03/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223274643 |
| Principal investigator 1 | Eli Lilly and Company | $819.01 | 01/31/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1187879871 |
| Principal investigator 1 | ABBVIE INC. | $134.64 | 01/30/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202443126 |
| Principal investigator 1 | Eli Lilly and Company | $212,746.04 | 01/29/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY OF LY4100511 (DC-853) FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1187881372 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,400.00 | 01/29/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175188914 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,318.00 | 01/29/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175188949 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,400.00 | 01/29/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189046 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,318.00 | 01/29/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189172 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,556.00 | 01/29/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189197 |
| Principal investigator 1 | Amgen Inc. | $35,089.23 | 01/27/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246640873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 01/24/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175188972 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 01/24/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175188981 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 01/24/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175189211 |
| Principal investigator 1 | Incyte Corporation | $1,548.00 | 01/17/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530949 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,484.00 | 01/16/2025 | Non-covered Recipient Entity Driven Rsrch Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175189029 |
| Principal investigator 1 | Eli Lilly and Company | $28,931.00 | 01/07/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1187880857 |
| Principal investigator 1 | Incyte Corporation | $273.60 | 01/07/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240530953 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $31,831.80 | 01/07/2025 | Non-covered Recipient Entity DRIVEN RESEARCH LLC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223273681 |